Design and Synthesis of Novel TLR2 Agonists for Regulating Tumor Microenvironment in Immunotherapy of Lung Cancer
Toll-like receptor 2 (TLR2) agonists hold great promise for cancer immunotherapy. Our previously identified TLR2 agonist SMU-Z1 contains a nitro group associated with potential metabolic toxicity. Herein, 47 analogs were designed and synthesized to mitigate toxicity, and SMU-H1 emerged as a potent, selective TLR2 ago...